Singapore markets closed

Fagron NV (0HNZ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
17.70-0.51 (-2.80%)
At close: 03:53PM BST
Full screen
Previous close18.21
Open18.00
Bid17.40 x 0
Ask18.28 x 0
Day's range17.66 - 18.00
52-week range14.65 - 19.08
Volume864
Avg. volume27,889
Market cap1.304B
Beta (5Y monthly)0.36
PE ratio (TTM)19.03
EPS (TTM)0.93
Earnings date01 Aug 2024
Forward dividend & yield0.25 (1.57%)
Ex-dividend date15 May 2023
1y target estN/A
  • GlobeNewswire

    Fagron shareholders approve all voting items at AGM and EGM

    Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders and extraordinary general meeting of shareholders today. Both meetings approved all. voting items. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30

  • GlobeNewswire

    Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

    Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the

  • GlobeNewswire

    Record revenue of €209 million in first quarter reflecting 15% topline growth

    Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regionsOrganic growth at CER of 12.3%